GGrantIndex
← Leaderboards

Antonio Abbate

University Of Virginia

Google Scholar ↗PubMed ↗ORCID ↗
$5,930,239
Attributed
$11,995,675
Total exposure
11
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.8M · FY2013–25
$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$11,995,675 · 11

By mechanism

R01$5,992,666 · 3
R33$2,240,366 · 1
R34$2,000,694 · 3
R21$841,775 · 2
R61$532,674 · 1
R56$387,500 · 1

Top collaborators

Most similar at University Of Virginia

Same institution · by research overlap

Others in their field

Top investigators on “Heart Failure”

Research focus

Heart FailureCardiacAnakinraCytokineInterleukin-1InflammationIncidenceInflammatoryHospitalizationQuality Of LifeInflammatory ResponseFunctional DisorderAcutePreventPrevalenceDouble-Blind MethodPlacebosSymptomsAnti-Inflammatory AgentsHeart FunctionAcute Myocardial InfarctionClinical TrialsDoseMortality

Grant awards (29)

Modeling of cell-specific LRP1 signaling in acute myocardial infarction$784,046
R01 · FY2025 · HL
Prevention of heart failure with IL-1 blockade: a mechanistic study$608,382
R01 · FY2025 · AG
Modeling of cell-specific LRP1 signaling in acute myocardial infarction$784,046
R01 · FY2024 · HL
Prevention of heart failure with IL-1 blockade: a mechanistic study$620,799
R01 · FY2024 · AG
Unconventional IL-1 Signaling in Heart failure$381,357
R01 · FY2024 · HL
Prevention of heart failure with IL-1 blockade: a mechanistic study$620,799
R01 · FY2023 · AG
Unconventional IL-1 Signaling in Heart failure$381,125
R01 · FY2023 · HL
Unconventional IL-1 signaling in heart failure$7,000
R01 · FY2023 · HL
Prevention of heart failure with IL-1 blockade: a mechanistic study$640,737
R01 · FY2022 · AG
The Effects of Interleukin-1 Blockade On Exercise Capacity In Patients With Recently Decompensated Systolic Heart Failure$573,435
R33 · FY2022 · HL
Unconventional IL-1 signaling in heart failure$388,125
R01 · FY2022 · HL
The Effects of Interleukin-1 Blockade On Exercise Capacity In Patients With Recently Decompensated Systolic Heart Failure$572,689
R33 · FY2021 · HL
Unconventional IL-1 signaling in heart failure$388,125
R01 · FY2021 · HL · contact PI
Feasibility and Safety of Interleukin-1 Blockade to Treat Cardiac Sarcoidosis$264,987
R21 · FY2021 · TR
The Effects of Interleukin-1 Blockade On Exercise Capacity In Patients With Recently Decompensated Systolic Heart Failure$547,121
R33 · FY2020 · HL
Unconventional IL-1 signaling in heart failure$388,125
R01 · FY2020 · HL · contact PI
Feasibility and Safety of Interleukin-1 Blockade to Treat Cardiac Sarcoidosis$226,174
R21 · FY2020 · TR · contact PI
The Effects of Interleukin-1 Blockade On Exercise Capacity In Patients With Recently Decompensated Systolic Heart Failure$547,121
R33 · FY2019 · HL
The Effects of Interleukin-1 Blockade On Exercise Capacity In Patients With Recently Decompensated Systolic Heart Failure$532,674
R61 · FY2018 · HL
New therapeutic targets in acute myocardial infarction$387,500
R56 · FY2017 · HL · contact PI
Interleukin-1 blockade in acute myocardial infarction$221,811
R34 · FY2016 · HL · contact PI
Interleukin-1 blockade in heart failure with preserved ejection fraction$337,978
R34 · FY2015 · HL · contact PI
Interleukin-1 blockade in acute myocardial infarction$212,907
R34 · FY2015 · HL · contact PI
Interleukin-1 blockade in heart failure with preserved ejection fraction$343,125
R34 · FY2014 · HL · contact PI
Interleukin-1 blockade in recently decompensated heart failure$340,316
R34 · FY2014 · HL
Interleukin-1 blockade in acute myocardial infarction$214,050
R34 · FY2014 · HL · contact PI
Protection from Radiation Induced Cardiomyopathy$156,260
R21 · FY2014 · CA
Interleukin-1 blockade in recently decompensated heart failure$330,507
R34 · FY2013 · HL
Protection from Radiation Induced Cardiomyopathy$194,354
R21 · FY2013 · CA